Aileron Therapeutics Amends 8-K, Updates Address & Confirms Nasdaq Listing
Ticker: RNTX · Form: 8-K/A · Filed: Jan 11, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics Inc (RNTX) |
| Form Type | 8-K/A |
| Filed Date | Jan 11, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative-update, SEC-filing, corporate-governance
TL;DR
**Aileron Therapeutics filed an 8-K/A, updating its address and confirming its Nasdaq listing.**
AI Summary
Aileron Therapeutics, Inc. filed an amended 8-K/A on January 11, 2024, clarifying its previous 8-K filing from October 30, 2023. This amendment primarily updates the company's address to 738 Main Street #398, Waltham, MA 02451, and confirms its listing on The Nasdaq Capital Market under the ticker ALRN. This matters to investors as it provides updated administrative details and reaffirms the company's compliance with SEC reporting requirements, ensuring transparency and continued trading on a major exchange.
Why It Matters
This filing provides updated administrative information for Aileron Therapeutics, Inc., confirming its current business address and its listing on The Nasdaq Capital Market, which is important for investor communication and market transparency.
Risk Assessment
Risk Level: low — This filing is an administrative amendment and does not contain any information that would significantly impact the company's financial health or operational risks.
Analyst Insight
A smart investor would note this administrative update as a routine compliance filing, confirming basic company details. It doesn't provide new financial or operational insights, so no immediate investment action is warranted based solely on this filing.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — the registrant filing the 8-K/A
- October 30, 2023 (date) — date of the earliest event reported in the original 8-K
- January 11, 2024 (date) — date the 8-K/A was filed
- 738 Main Street #398, Waltham, MA 02451 (address) — Aileron Therapeutics' updated business and mail address
- ALRN (company) — trading symbol for Aileron Therapeutics
- The Nasdaq Capital Market (company) — exchange where Aileron Therapeutics' common stock is registered
FAQ
What is the purpose of this 8-K/A filing by Aileron Therapeutics, Inc.?
This 8-K/A filing is an amendment to a previous 8-K, primarily to update and clarify administrative information, specifically the company's business address and to confirm its listing on The Nasdaq Capital Market.
What is the updated business address for Aileron Therapeutics, Inc. as stated in this filing?
The updated business address for Aileron Therapeutics, Inc. is 738 Main Street #398, Waltham, MA 02451, with a business phone number of (617) 995-0900.
On which stock exchange is Aileron Therapeutics, Inc.'s common stock registered?
Aileron Therapeutics, Inc.'s Common Stock, $0.001 par value per share, is registered on The Nasdaq Capital Market under the trading symbol ALRN.
What was the date of the earliest event reported in the original 8-K that this filing amends?
The date of the earliest event reported in the original 8-K, which this 8-K/A amends, was October 30, 2023.
When was this 8-K/A filing submitted to the SEC?
This 8-K/A filing was filed with the SEC on January 11, 2024.
Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 10.2 · Accepted 2024-01-11 16:18:05
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d22567d8ka.htm (8-K/A) — 30KB
- d22567dex231.htm (EX-23.1) — 3KB
- d22567dex991.htm (EX-99.1) — 333KB
- d22567dex992.htm (EX-99.2) — 305KB
- d22567dex993.htm (EX-99.3) — 286KB
- 0001193125-24-006614.txt ( ) — 1200KB
- alrn-20231030.xsd (EX-101.SCH) — 2KB
- alrn-20231030_lab.xml (EX-101.LAB) — 18KB
- alrn-20231030_pre.xml (EX-101.PRE) — 11KB
- d22567d8ka_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits (a) Financial statements of businesses or funds acquired. The financial statements required by Item 9.01(a) and the notes related thereto are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K/A. (b) Pro forma financial information. The pro forma financial information required by Item 9.01(b) and the notes related thereto are filed as Exhibit 99.3 to this Current Report on Form 8-K/A. (d) Exhibits Exhibit No. Description 23.1 Consent of Deloitte LLP 99.1 Audited Consolidated Financial Statements of Lung Therapeutics, Inc. for the years ended December 31, 2022 and 2021 99.2 Unaudited Condensed Consolidated Financial Statements of Lung Therapeutics, Inc. for the nine months ended September 30, 2023 and 2022 99.3 Unaudited Pro Forma Condensed Combined Financial Information of Aileron Therapeutics, Inc. and Lung Therapeutics, Inc. as of September 30, 2023 and for the nine months ended September 30 2023 and for the year ended December 31, 2022 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AILERON THERAPEUTICS, INC. Date: January 11, 2024 By: /s/ Manuel C. Alves-Aivado, M.D., Ph.D. Manuel C. Alves-Aivado, M.D., Ph.D. Chief Executive Officer